See how combining human oversight with AI insights improves protocol authorship, site selection, and monitoring strategies, ...
New data show that applying AI to the migration of translated COAs into eCOA platforms can meaningfully reduce errors, accelerate localization workflows, and support broader global patient ...
In today’s ACT Brief, we highlight new insights from McKinsey on where AI can meaningfully accelerate clinical development, break down the emerging design and regulatory forces reshaping obesity drug ...
In today’s ACT Brief, we break down FDA’s new superiority requirement reshaping CAR-T development, examine Pfizer’s global ...
Explore how AI can optimize study design, speed patient recruitment, and streamline operational workflows to shorten ...
In today’s ACT Brief, we explore how stronger vendor–sponsor governance is speeding eCOA study startup, hear from AMR ...
Gain insights into the operational challenges facing clinical research sites today, learn what sponsors and CROs can do to ...
As highly effective anti-obesity therapies emerge and regulatory expectations evolve, sponsors are adopting innovative trial designs, addressing long-term weight maintenance, monitoring lean mass ...
ACT: As new ICH GCP guidelines roll out, how are sponsors balancing the drive for innovation—especially in areas like CAR-T ...
For industry-sponsored trials in autoimmune inflammation therapeutic areas, the dominating indications include atopic ...
Strong relational governance between technology vendors and sponsor–CRO teams is becoming a critical foundation for eCOA ...
New FDA guidance signals a major shift for CAR-T development, calling for randomized trials with standard-of-care control groups and clear evidence of superiority over existing therapies, while ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback